Lorukafusp alfa
- Generic Name
- Lorukafusp alfa
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 2131168-99-3
- Unique Ingredient Identifier
- PL21OR4LXE
- Background
Lorukafusp alfa is under investigation in clinical trial NCT01334515 (Biological Therapy, Sargramostim, and Isotretinoin in Treating Patients With Relapsed or Refractory Neuroblastoma).
- Associated Conditions
- -
- Associated Therapies
- -
IT-hu14.18-IL2 With Radiation, Nivolumab and Ipilimumab for Melanoma
Phase 1
Suspended
- Conditions
- Interventions
- First Posted Date
- 2019-05-22
- Last Posted Date
- 2024-02-14
- Lead Sponsor
- University of Wisconsin, Madison
- Target Recruit Count
- 61
- Registration Number
- NCT03958383
- Locations
- 🇺🇸
University of Wisconsin Carbone Cancer Center, Madison, Wisconsin, United States
Pilot hu14.18-IL2 in Resectable Recurrent Stage III or Stage IV Melanoma
- First Posted Date
- 2008-01-11
- Last Posted Date
- 2019-11-21
- Lead Sponsor
- University of Wisconsin, Madison
- Target Recruit Count
- 23
- Registration Number
- NCT00590824
- Locations
- 🇺🇸
University of Wisconsin Hospitals and Clinics, Madison, Wisconsin, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath